MENU
jpma
  • Access
  • Japanese
  • Global Health

    Global Health TOP

    • Sustainable Development Goals, SDGs
    • Universal Health Coverage
    • Value and Access of medicines
    • Intellectual Property (IP)
    • Infectious Diseases
    • Non-Communicable Diseases (NCDs)
    • Countermeasures against Counterfeit Medicines
    • Global Health Issues
    • JPMA Position Statements
    • JPMA Global Health Events
  • Activities

    Activities TOP

    • International Affairs Committee(Asia Committee)
    • Pharmaceutical Industrial Policy Committee
    • Deliverables of Drug Evaluation Committee
    • Quality & Technology Committee
    • R & D Committee
    • Others
  • Code

    Code TOP

    • JPMA Industry Vision 2025
    • JPMA Charter of Corporate Behavior
    • Code of Practice
    • Transparency Guideline
    • Intellectual Property
    • Global Health
  • About Us

    About Us TOP

    • About JPMA
    • President's Message
    • Officers
    • Structure of JPMA
    • Related Organizations
    • Member Companies
    • Video
    • Access
    • JPMA Industry Vision 2025
    • Pharmaceutical Regulations in Japan
  • ICH Project

    ICH Project TOP

    • ICH Public Meetings
    • ICH-branded regional meetings
    • Implementation Training Workshop
    • ICH Guideline/Implementation Guide related materials (Translation into English/Japanese)
  • News Room

    News Room TOP

    • News Release
    • Information
Close

Site TOP

  • Global Health
    Global Health TOP
    • Sustainable Development Goals, SDGs
    • Universal Health Coverage
    • Value and Access of medicines
    • Intellectual Property (IP)
    • Infectious Diseases
    • Non-Communicable Diseases (NCDs)
    • Countermeasures against Counterfeit Medicines
    • Global Health Issues
    • JPMA Position Statements
    • JPMA Global Health Events
  • Code
    Code TOP
    • JPMA Industry Vision 2025
    • JPMA Charter of Corporate Behavior
    • Code of Practice
    • Transparency Guideline
    • Intellectual Property
    • Global Health
  • About Us
    About Us TOP
    • About JPMA
    • President's Message
    • Officers
    • Structure of JPMA
    • Related Organizations
    • Member Companies
    • Video
    • Access
    • JPMA Industry Vision 2025
    • Pharmaceutical Regulations in Japan
  • ICH Project
    ICH Project TOP
    • ICH Public Meetings
    • ICH-branded regional meetings
    • Implementation Training Workshop
    • ICH Guideline/Implementation Guide related materials (Translation into English/Japanese)
  • News Room
    News Room TOP
    • News Release
    • Information
  • Asia Partnership Conference of Pharmaceutical Associations(APAC)
  • Access
  • Japanese
  • Home
  • Activities
  • Others

Others

  • JPMA Statement on WTO TRIPS Intellectual Property Waiver
  • Three priorities to urgently increase access to COVID-19 vaccines
  • Statement by JPMA President on the Passing of Former Prime Minister ABE Shinzo
  • Opinion on Access and Benefit Sharing of Digital Sequence Information
  • UN Climate Change Conference (COP26): Biopharmaceutical Industry Actions to Tackle Climate Change
  • Innovative pharmaceutical industry statement on COP28 Declaration on Climate and Health
  • The“JAPANESE CONSENSUS FRAMEWORK FOR ETHICAL COLLABORATION" received the "2023 The Lighthouse Award" for its activities.

share

  • Tweet
  • share

TOP

Search

  • Home
  • Activities
  • Others
  • Global Health
  • JPMA Committee Activities
  • Code
  • About Us
  • ICH
  • OPIROpen link in new window.
  • X
  • facebook
  • youtube
  • Sitemap
  • Link

© Japan Pharmaceutical Manufacturers
Association(JPMA).All rights reserved.